Research programme: GPCR modulators - metabolic disorders - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - metabolic disorders - Heptares Therapeutics

Alternative Names: G protein-coupled receptor 39 agonists; G protein-coupled receptor modulators; GLP-1 antagonists; Glucagon-like peptide 1 antagonists; GPR39 modulators

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical Research Council
  • Developer Heptares Therapeutics; Medical Research Council
  • Class Small molecules
  • Mechanism of Action Glucagon-like peptide 1 receptor modulators; Glucagon-like peptide-1 receptor antagonists; GPR39 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hyperinsulinaemia; Hypoglycaemia
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in United Kingdom (PO)
  • 25 Apr 2016 Early research in Hyperinsulinaemia in United Kingdom (unspecified route)
  • 23 Feb 2015 Heptares Therapeutics has been acquired by Sosei
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top